List of Ortikos drug patents

Ortikos is owned by Sun Pharm Inds Inc.

Ortikos contains Budesonide.

Ortikos has a total of 2 drug patents out of which 0 drug patents have expired.

Ortikos was authorised for market use on 13 June, 2019.

Ortikos is available in capsule, extended release;oral dosage forms.

Ortikos can be used as treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon.

The generics of Ortikos are possible to be released after 09 September, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9707182 SUN PHARM INDS INC Oral pharmaceutical dosage forms of budesonide
Sep, 2036

(13 years from now)

US10172802 SUN PHARM INDS INC Oral pharmaceutical dosage forms of budesonide
Sep, 2036

(13 years from now)

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 13 June, 2019

Treatment: Treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in